Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

CNCE

Concert Pharmaceuticals (CNCE)

Concert Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CNCE
FechaHoraFuenteTítuloSímboloCompañía
03/09/201906:00Business WireConcert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata TrialNASDAQ:CNCEConcert Pharmaceuticals Inc
29/08/201906:00Business WireConcert Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:CNCEConcert Pharmaceuticals Inc
19/08/201905:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNCEConcert Pharmaceuticals Inc
01/08/201906:40Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CNCEConcert Pharmaceuticals Inc
01/08/201906:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNCEConcert Pharmaceuticals Inc
01/08/201906:00Business WireConcert Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company UpdateNASDAQ:CNCEConcert Pharmaceuticals Inc
25/07/201906:00Business WireConcert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019NASDAQ:CNCEConcert Pharmaceuticals Inc
03/07/201914:32Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CNCEConcert Pharmaceuticals Inc
12/06/201906:00Business WireConcert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy VolunteersNASDAQ:CNCEConcert Pharmaceuticals Inc
05/06/201906:00Business WireConcert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in ...NASDAQ:CNCEConcert Pharmaceuticals Inc
16/05/201906:00Business WireConcert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543...NASDAQ:CNCEConcert Pharmaceuticals Inc
08/05/201916:16Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNCEConcert Pharmaceuticals Inc
02/05/201906:00Business WireConcert Pharmaceuticals Reports First Quarter 2019 Financial ResultsNASDAQ:CNCEConcert Pharmaceuticals Inc
29/04/201906:23Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CNCEConcert Pharmaceuticals Inc
29/04/201906:00Business WireConcert Pharmaceuticals Names Jesper Høiland to its Board of DirectorsNASDAQ:CNCEConcert Pharmaceuticals Inc
25/04/201906:00Business WireConcert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019NASDAQ:CNCEConcert Pharmaceuticals Inc
11/04/201906:00Business WireConcert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research A...NASDAQ:CNCEConcert Pharmaceuticals Inc
10/04/201905:30Business WireConcert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for SchizophreniaNASDAQ:CNCEConcert Pharmaceuticals Inc
08/04/201913:45Business WireConcert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR ProceedingNASDAQ:CNCEConcert Pharmaceuticals Inc
25/03/201911:26Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNCEConcert Pharmaceuticals Inc
12/03/201906:00Business WireConcert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare ConferenceNASDAQ:CNCEConcert Pharmaceuticals Inc
06/03/201906:00Business WireConcert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in ...NASDAQ:CNCEConcert Pharmaceuticals Inc
01/03/201915:50Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CNCEConcert Pharmaceuticals Inc
01/03/201906:00Business WireConcert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Acad...NASDAQ:CNCEConcert Pharmaceuticals Inc
28/02/201906:28Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CNCEConcert Pharmaceuticals Inc
28/02/201906:25Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CNCEConcert Pharmaceuticals Inc
28/02/201906:00Business WireConcert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical ProgramsNASDAQ:CNCEConcert Pharmaceuticals Inc
21/02/201906:00Business WireConcert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019NASDAQ:CNCEConcert Pharmaceuticals Inc
11/02/201906:00Business WireConcert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD A...NASDAQ:CNCEConcert Pharmaceuticals Inc
24/01/201906:00Business WireConcert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for SchizophreniaNASDAQ:CNCEConcert Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CNCE

Su Consulta Reciente

Delayed Upgrade Clock